Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

被引：4
|
作者：
Garnock-Jones, Karly P. [1 ]
Keating, Gillian M. [1 ]
Scott, Lesley J. [1 ]
机构：
[1] Adis, Auckland, New Zealand
来源：
BIODRUGS | 2010年 / 24卷 / 03期
关键词：
COMPLEX-FORMATION; HERCEPTIN; CHEMOTHERAPY; DOXORUBICIN; INHIBITION; MODULATION; PACLITAXEL; MECHANISM; ANTIBODY; SUBTYPES;
D O I：
10.2165/11204680-000000000-00000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：207 / 209
页数：3
相关论文
共 50 条
  • [41] Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
    Piccart-Gebhart, Martine
    Holmes, Eileen
    Baselga, Jose
    de Azambuja, Evandro
    Dueck, Amylou C.
    Viale, Giuseppe
    Zujewski, Jo Anne
    Goldhirsch, Aron
    Armour, Alison
    Pritchard, Kathleen I.
    McCullough, Ann E.
    Dolci, Stella
    McFadden, Eleanor
    Holmes, Andrew P.
    Liu Tonghua
    Eidtmann, Holger
    Phuong Dinh
    Di Cosimo, Serena
    Harbeck, Nadia
    Tjulandin, Sergei
    Im, Young-Hyuck
    Huang, Chiun-Sheng
    Dieras, Veronique
    Hillman, David W.
    Wolff, Antonio C.
    Jackisch, Christian
    Lang, Istvan
    Untch, Michael
    Smith, Ian
    Boyle, Frances
    Xu, Binghe
    Gomez, Henry
    Suter, Thomas
    Gelber, Richard D.
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1034 - +
  • [42] Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer
    Kawaguchi, Hidetoshi
    Yamashita, Toshinari
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Kawasoe, Teru
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER RESEARCH, 2018, 78 (04)
  • [43] A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Komal Jhaveri
    Rui Wang
    Eleonora Teplinsky
    Sarat Chandarlapaty
    David Solit
    Karen Cadoo
    James Speyer
    Gabriella D’Andrea
    Sylvia Adams
    Sujata Patil
    Sofia Haque
    Tara O’Neill
    Kent Friedman
    Francisco J. Esteva
    Clifford Hudis
    Shanu Modi
    Breast Cancer Research, 19
  • [44] Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario
    Earle, Craig
    Ferrusi, Ilia L.
    Trudeau, Maureen E.
    Leighl, Natasha B.
    Pullenayegum, Eleanor
    Khong, Hoa
    Hoch, Jeffrey
    Marshall, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [45] A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Jhaveri, Komal
    Wang, Rui
    Teplinsky, Eleonora
    Chandarlapaty, Sarat
    Solit, David
    Cadoo, Karen
    Speyer, James
    D'Andrea, Gabriella
    Adams, Sylvia
    Patil, Sujata
    Haque, Sofia
    O'Neill, Tara
    Friedman, Kent
    Esteva, Francisco J.
    Hudis, Clifford
    Modi, Shanu
    BREAST CANCER RESEARCH, 2017, 19
  • [46] Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021
    Mezni, Essia
    Sabatier, Renaud
    Goncalves, Anthony
    Vicier, Cecile
    BULLETIN DU CANCER, 2022, 109 (02) : 216 - 225
  • [47] Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan
    Nusawat, Chanon
    Sato, So
    Watanabe, Hideaki
    Konishi, Takaaki
    Yamana, Hayato
    Yasunaga, Hideo
    CLINICAL DRUG INVESTIGATION, 2024, 44 (12) : 927 - 938
  • [48] Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer
    Patel, Kiki
    Hageman, Kelly
    Cooper, Maryann
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (07) : 537 - 548
  • [49] NON-INTERVENTIONAL, REAL-WORLD STUDY OF PATIENTS WITH EARLY STAGE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE BREAST CANCER RECEIVING BIOSIMILAR TRASTUZUMAB
    Shelbaya, A.
    Kale, H.
    Poorman, G.
    Inguva, S.
    Alvir, J. M.
    Bair, A.
    Stephens, J. M.
    VALUE IN HEALTH, 2022, 25 (07) : S489 - S489
  • [50] Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions
    Nanda, Rita
    REVIEWS ON RECENT CLINICAL TRIALS, 2007, 2 (02) : 111 - 116
12345